EA201890009A1 - Ингибиторы ezh2 для лечения лимфомы - Google Patents

Ингибиторы ezh2 для лечения лимфомы

Info

Publication number
EA201890009A1
EA201890009A1 EA201890009A EA201890009A EA201890009A1 EA 201890009 A1 EA201890009 A1 EA 201890009A1 EA 201890009 A EA201890009 A EA 201890009A EA 201890009 A EA201890009 A EA 201890009A EA 201890009 A1 EA201890009 A1 EA 201890009A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ezh2 inhibitors
treating lymphoma
ezh2
inhibitors
lymphoma
Prior art date
Application number
EA201890009A
Other languages
English (en)
Inventor
Хайке Кайльхак
Сара К. Натсон
Л. Дэниелль Джонстон
Original Assignee
Эпизайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк. filed Critical Эпизайм, Инк.
Publication of EA201890009A1 publication Critical patent/EA201890009A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers

Abstract

Изобретение относится к композициям, содержащим ингибиторы метилтрансферазы гистонов EZH2 человека и одно или несколько других терапевтических средств, в частности противораковые средства, такие как преднизон, а также к способам комбинированной терапии для введения субъектам, нуждающимся в этом, для лечения рака.
EA201890009A 2015-06-10 2016-06-10 Ингибиторы ezh2 для лечения лимфомы EA201890009A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173685P 2015-06-10 2015-06-10
PCT/US2016/037024 WO2016201328A1 (en) 2015-06-10 2016-06-10 Ezh2 inhibitors for treating lymphoma

Publications (1)

Publication Number Publication Date
EA201890009A1 true EA201890009A1 (ru) 2018-07-31

Family

ID=57504554

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890009A EA201890009A1 (ru) 2015-06-10 2016-06-10 Ингибиторы ezh2 для лечения лимфомы

Country Status (10)

Country Link
US (3) US20180311251A1 (ru)
EP (1) EP3307713A4 (ru)
JP (1) JP6890097B2 (ru)
CN (1) CN107635965A (ru)
AU (2) AU2016275051A1 (ru)
CA (1) CA2988816A1 (ru)
EA (1) EA201890009A1 (ru)
IL (1) IL256056A (ru)
MX (2) MX2017015938A (ru)
WO (1) WO2016201328A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
CN106999498B (zh) 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
BR112017010166A2 (pt) * 2014-11-17 2018-02-14 Eisai R&D Man Co Ltd método de tratamento de um tumor sólido, método de inibição da atividade, forma de dosagem oral para o tratamento de um tumor sólido, formulação farmacêutica sólida, processo para a preparação de uma formulação farmacêutica, e, composição farmacêutica sólida
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
MX2019008458A (es) 2017-01-17 2019-12-02 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
WO2019133674A1 (en) * 2017-12-28 2019-07-04 Constellation Pharmaceuticals, Inc. Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US20210393601A1 (en) * 2018-11-29 2021-12-23 Daiichi Sankyo Company, Limited Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug
WO2020165402A1 (en) * 2019-02-14 2020-08-20 Westfälische Wilhelms-Universität Münster Gd2-upregulation by ezh2 inhibition in cancer therapy
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
CN111303133A (zh) * 2020-03-25 2020-06-19 清华大学 降解ezh2蛋白的小分子化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012028556A2 (pt) * 2010-05-07 2014-04-01 Glaxosmithkline Llc Indóis
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
CA2850570A1 (en) * 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
ES2718900T3 (es) 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
KR20230004871A (ko) * 2012-04-13 2023-01-06 에피자임, 인코포레이티드 암 치료용 병용 요법
SG11201406468YA (en) 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
PE20150887A1 (es) * 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
NZ706836A (en) 2012-10-15 2019-02-22 Epizyme Inc Methods of treating cancer
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
PT2914296T (pt) 2012-11-01 2018-10-30 Infinity Pharmaceuticals Inc Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
AU2014254392B2 (en) 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
AU2014337300B2 (en) 2013-10-16 2019-01-03 Eisai R&D Management Co., Ltd. Hydrochloride salt form for EZH2 inhibition
JP2016533364A (ja) 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
CN106999498B (zh) 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX2017004969A (es) 2014-10-16 2017-07-19 Epizyme Inc Metodo para tratar el cancer.
US20190000860A1 (en) * 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
BR112017010166A2 (pt) 2014-11-17 2018-02-14 Eisai R&D Man Co Ltd método de tratamento de um tumor sólido, método de inibição da atividade, forma de dosagem oral para o tratamento de um tumor sólido, formulação farmacêutica sólida, processo para a preparação de uma formulação farmacêutica, e, composição farmacêutica sólida
JP6544507B2 (ja) 2015-02-09 2019-07-17 日本精機株式会社 ヘッドアップディスプレイ装置
EP3285773A4 (en) 2015-04-20 2019-04-10 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
KR20170095656A (ko) 2016-02-15 2017-08-23 동부대우전자 주식회사 방열구조를 갖는 세탁기

Also Published As

Publication number Publication date
CN107635965A (zh) 2018-01-26
EP3307713A1 (en) 2018-04-18
MX2017015938A (es) 2018-11-09
AU2016275051A1 (en) 2017-12-07
AU2021201705A1 (en) 2021-04-08
US20190255060A1 (en) 2019-08-22
MX2021013830A (es) 2022-03-17
WO2016201328A1 (en) 2016-12-15
JP2018524298A (ja) 2018-08-30
US20220175789A1 (en) 2022-06-09
US11951109B2 (en) 2024-04-09
JP6890097B2 (ja) 2021-06-18
US20180311251A1 (en) 2018-11-01
US11202781B2 (en) 2021-12-21
IL256056A (en) 2018-01-31
CA2988816A1 (en) 2016-12-15
EP3307713A4 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2017013142A (es) Terapia combinada para tratar cáncer.
WO2016025635A3 (en) Combination therapy for treating cancer
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2021006734A (es) Metodo para tratar el cancer.
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
EA201591925A1 (ru) Терапевтические композиции и их применение
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
WO2016043874A3 (en) Combination therapy for treating cancer
EA201890567A1 (ru) Способ лечения рака
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
PH12020500666A1 (en) Pladienolide compounds and their use
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EA202190294A1 (ru) Комбинированная терапия для лечения рака